{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-089912","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2026-08-14T19:11:19+00:00","discovered_at":"2026-08-14T19:12:32.374050+00:00","generated_at":"2026-08-14T19:12:37.348471+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Emmaus Q2 2026 net income $1.3M vs $1.1M loss; revenue up 124% on NIT license","bullets":["Net revenues $6.3M for Q2 2026 vs $2.8M in Q2 2025, driven by NIT license revenue recognition.","Operating expenses fell to $2.1M from $3.0M; income from operations $3.8M vs $0.4M loss.","Net income $1.3M ($0.02 EPS) vs net loss $1.1M (-$0.02 EPS); cash $2.8M at June 30, 2026.","NIT exclusive license for Endari in US/Canada effective May 15, 2026; upfront payment and royalties recognized.","Weighted-average shares 70.2M vs 63.9M in prior-year quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-089912","json":"https://secwatch.observer/filing/0001213900-26-089912.json","markdown":"https://secwatch.observer/filing/0001213900-26-089912.md","text":"https://secwatch.observer/filing/0001213900-26-089912.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390026089912/0001213900-26-089912-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390026089912/ea0302099-8k_emmaus.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T19:12:37.348471+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}